Cargando…

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

BACKGROUND: The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camacho-Toledano, Celia, Machín-Díaz, Isabel, Calahorra, Leticia, Cabañas-Cotillas, María, Otaegui, David, Castillo-Triviño, Tamara, Villar, Luisa María, Costa-Frossard, Lucienne, Comabella, Manuel, Midaglia, Luciana, García-Domínguez, José Manuel, García-Arocha, Jennifer, Ortega, María Cristina, Clemente, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675277/ https://www.ncbi.nlm.nih.gov/pubmed/36403026 http://dx.doi.org/10.1186/s12974-022-02635-3

Ejemplares similares

Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis
por: Ortega, María Cristina, et al.
Publicado: (2023)

Regulatory Cells in Multiple Sclerosis: From Blood to Brain
por: Calahorra, Leticia, et al.
Publicado: (2022)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

Whole-Transcriptome Analysis in Peripheral Blood Mononuclear Cells from Patients with Lipid-Specific Oligoclonal IgM Band Characterization Reveals Two Circular RNAs and Two Linear RNAs as Biomarkers of Highly Active Disease
por: Iparraguirre, Leire, et al.
Publicado: (2020)

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients
por: Sáenz-Cuesta, Matías, et al.
Publicado: (2018)

Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non‐cell‐autonomous neuronal damage
por: Matute‐Blanch, Clara, et al.
Publicado: (2022)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2023)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
por: Gil-Varea, Elia, et al.
Publicado: (2020)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod
por: Piñar Morales, Raquel, et al.
Publicado: (2022)

Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis
por: Alcina, Antonio, et al.
Publicado: (2022)

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
por: Malhotra, Sunny, et al.
Publicado: (2018)

Should We Be Trained to Train? Nursing Students’ and Newly Qualified Nurses’ Perception on Good Lecturers and Good Clinical Preceptors
por: Martínez-Linares, José Manuel, et al.
Publicado: (2019)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2022)

Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage
por: Gil, Antonio, et al.
Publicado: (2020)

In silico Docking Studies of Fingolimod and S1P(1) Agonists
por: Marciniak, Alexander, et al.
Publicado: (2020)

Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study
por: Gesualdo, Carlo, et al.
Publicado: (2021)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression
por: Pérez-Pérez, Silvia, et al.
Publicado: (2021)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells
por: Mena, Jorge, et al.
Publicado: (2022)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress
por: Andrés, Celia María Curieses, et al.
Publicado: (2023)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Electrochemical Technologies to Decrease the Chemical Risk of Hospital Wastewater and Urine
por: Moratalla, Ángela, et al.
Publicado: (2021)

Mediastinal abscess and osteomyelitis as side effects of immunomodulatory treatment with fingolimod
por: Eforakopoulos, Fotios, et al.
Publicado: (2022)

Neurological safety of fingolimod: An updated review
por: Yoshii, Fumihito, et al.
Publicado: (2017)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Differential Biodegradation Kinetics of Collagen Membranes for Bone Regeneration
por: Toledano, Manuel, et al.
Publicado: (2020)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2021)

Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
por: Hjorth, Maria, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good
por: Grassi, Germana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5p0cs2ti57hl3ccu3k1ebgd4ds